Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Canadian Clinical Site Approvals too Long

View:

Post by Viking2233 on Aug 19, 2024 9:30am

Canadian Clinical Site Approvals too Long

Here is another article below on the approval process for clinical trials done in Canada.

The approval process takes 6-12 months.

We announced our Canadian sites in March & April 2024 so we are 4-5 months into the process.

We potentially could be looking into spring of 2025 before dosing starts in Canada or potentially never even dosing in Canada as we are currently dosing at 5 sites in Turkey.

Now all of this approval process is out of the control of Arch.

This is another reason we have a bullseye on our back and been attacked by algorithm short traders.

One needs to think how this lengthy process impacts our announced Pontiac Trial slated for fall of 2024. I would not be banking on it starting until later 2025 based on what I am reading.

There were many trials planned for covid that never even got to dosing due to the lengthy approval process.

https://www.cmaj.ca/content/195/14/E517

185